Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOURLIGHT-1
jRCT2051230196Phase 2Active, not recruiting
- Sponsor
- Pfizer
- Start
- May 2024
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of atirmociclib, fulvestrant, everolimus and exemestane in breast cancer (2 arms), sponsored by Pfizer. Primary endpoint: Progression-Free Survival. Started May 2024; status: active, not recruiting.
02
Drugs
atirmociclibfulvestranteverolimusexemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2051230196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051230196.